KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $23.4 million.

  • Emergent BioSolutions' Depreciation & Amortization (CF) fell 11.36% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.3 million, marking a year-over-year decrease of 12.54%. This contributed to the annual value of $108.8 million for FY2024, which is 13.03% down from last year.
  • Per Emergent BioSolutions' latest filing, its Depreciation & Amortization (CF) stood at $23.4 million for Q3 2025, which was down 0.43% from $23.5 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Depreciation & Amortization (CF) registered a high of $44.5 million during Q2 2022, and its lowest value of $23.4 million during Q3 2025.
  • For the 3-year period, Emergent BioSolutions' Depreciation & Amortization (CF) averaged around $27.8 million, with its median value being $27.9 million (2024).
  • As far as peak fluctuations go, Emergent BioSolutions' Depreciation & Amortization (CF) soared by 34.04% in 2022, and later decreased by 26.07% in 2023.
  • Emergent BioSolutions' Depreciation & Amortization (CF) (Quarterly) stood at $29.2 million in 2021, then climbed by 22.26% to $35.7 million in 2022, then dropped by 17.09% to $29.6 million in 2023, then dropped by 12.16% to $26.0 million in 2024, then declined by 11.36% to $23.4 million in 2025.
  • Its last three reported values are $23.4 million in Q3 2025, $23.5 million for Q2 2025, and $25.4 million during Q1 2025.